EP Patent

EP3668515A4 — Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis

Assigned to Neurocrine Biosciences Inc · Expires 2021-05-12 · 5y expired

What this patent protects

Patent listed against elagolix-sodium.

Drugs covered by this patent

elagolix-sodium (ELAGOLIX SODIUM)

Patent Metadata

Patent number: EP3668515A4
Jurisdiction: EP
Classification: —
Expires: 2021-05-12
Drug substance claim: No
Drug product claim: No
Assignee: Neurocrine Biosciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.